A BMJ report in 2015
confirmed that near 20% of Taiwanese carry HLA-B*58:01, a genetic variant associated with allopurinol-induced severe cutaneous adverse reactions (SCARs).
This has caused the shifting of prescribing medication for gout from
Allopurinol (#M04AA01)
to
Febuxostat (#M04AA03)
in the 2010s.
